BMSD : 10.65048
BMSD : 10.65048
https://doi.org/10.65048/ijbmr
Search
About Us
Authors
Reviewers
Editorial Board
Contact Us

Antimicrobial peptides as next-generation anticancer therapeutics: mechanisms, advanced drug delivery systems, and the frontier of precision oncology

Authors:Rokonuzzaman,MD Nazmul Islam
Int J Biol Med Res. 2026; 17(4): 8937-8960  |  PDF File  |  Full Text
DOI No.: 10.65048/ijbmr.2026.17.4.8937.1118

Abstract

Antimicrobial peptides (AMPs) have emerged as a highly promising frontier in precision oncology, offering novel therapeutic mechanisms that distinctly differentiate them from conventional chemotherapeutic agents. This review comprehensively examines the major classifications of AMPs utilized in cancer research—including human, animal, marine, plant, and bacterial-derived sequences—alongside recent innovations in synthetic and structurally modified peptide engineering. The primary anticancer efficacy of AMPs stems from their cationic and amphipathic nature, which enables selective electrostatic targeting and mechanical disruption of negatively charged cancer cell membranes, effectively bypassing traditional multi-drug resistance pathways. Beyond direct membrane-lytic cytotoxicity, AMPs induce programmed cell death via mitochondrial depolarization, suppress tumor-supportive angiogenesis, and actively remodel the immunosuppressive tumor microenvironment to potentiate host adaptive immunity. Furthermore, we evaluate the expanding role of AMPs as advanced drug delivery vehicles, focusing on cell-penetrating peptides, peptide-drug conjugates, and self-assembling nanostructured hydrogels that optimize the delivery of traditional chemotherapeutic payloads across challenging biological barriers. Despite extraordinary preclinical success across diverse malignancies such as breast, lung, colorectal, and glioblastoma models, systemic clinical translation faces significant pharmacological hurdles, including low proteolytic stability in biological fluids, rapid renal clearance, off-target hemolysis, and high manufacturing costs. To bridge this translational gap, current research strategies are heavily leveraging rational sequence modifications, d-amino acid incorporation, chemical stapling, and smart stimuli-responsive nanocarriers. Ultimately, the integration of artificial intelligence and deep machine learning for de novo peptide design, paired with personalized neoantigen peptide profiling, promises to transform antimicrobial peptides from experimental laboratory candidates into highly selective, low-toxicity cornerstones of next-generation precision oncology.